In today’s briefing:
- Molina Healthcare’s Medical Cost Crisis – How They’re Fighting Back!
- Centene Corporation: Medicare Segment Growth Driving Our Bullishness!
- Elevance Health: Expansion of Carelon Services to Contribute Positively To Revenue Streams!
- Duality Biotherapeutics (映恩生物) Pre-IPO: PHIP Updates Show Slight Improvements
- Masimo Corporation: The Strong Contracting
- 3 D Matrix Ltd (7777 JP): Q3 FY04/25 flash update
- Henry Schein: These Are The 5 Biggest Challenges That Could Hinder Its Growth in Future!
- MIRA: Pain Management Options Expand
- MIRA: Pain Management Options Expand
- MIRA: Pain Management Options Expand
Molina Healthcare’s Medical Cost Crisis – How They’re Fighting Back!
- Molina Healthcare’s fourth-quarter and full-year 2024 results present a mixed picture, reflecting both challenges and prospects for future growth.
- The company reported an adjusted EPS of $5.05 for the fourth quarter and $22.65 for the full year, which represents an 8.5% year-over-year growth.
- However, the fourth-quarter results did not meet the company’s internal expectations due to higher-than-anticipated medical cost pressure in the Medicaid and Medicare segments, leading to a consolidated medical care ratio (MCR) of 90.2% for the quarter, which was above forecasts.
Centene Corporation: Medicare Segment Growth Driving Our Bullishness!
- Centene Corporation’s recent performance exhibited both strengths and areas for careful attention.
- The company’s financial results for the fourth quarter of 2024 demonstrated solid earnings power, with adjusted diluted earnings per share (EPS) of $0.80 and a full-year EPS of $7.17.
- This growth is attributed to robust performance across its business lines, including Medicare and Medicaid, and significant operational improvements.
Elevance Health: Expansion of Carelon Services to Contribute Positively To Revenue Streams!
- Elevance Health, formerly known as Anthem, reported a fourth-quarter GAAP diluted earnings per share of $1.81 and adjusted EPS of $3.84, matching previous expectations.
- The adjusted EPS for the full year reached $33.04.
- Total operating revenue for 2024 was $175.2 billion, a 3% increase from the prior year, reflecting strategic premium rate adjustments and growth within its Carelon businesses.
Duality Biotherapeutics (映恩生物) Pre-IPO: PHIP Updates Show Slight Improvements
- Duality Biotherapeutics, a China-based clinical-stage biotechnology company, plans to raise up to US$300m via a Hong Kong listing.
- The company has passed the hearing for the listing and filed a new version of the prospectus.
- We look at the difference between previous filing and current filing.
Masimo Corporation: The Strong Contracting
- Masimo Corporation reported its fourth quarter and full-year 2024 financial results, highlighting both accomplishments and areas that require attention.
- On the positive side, the company exhibited solid performance with consolidated revenues for the fourth quarter reaching $601 million, representing a 9% increase on a constant currency basis.
- Healthcare revenues grew by 9% to $368 million, which was bolstered by the shipment of 65,000 technology boards and monitors, reaching the high end of expectations.
3 D Matrix Ltd (7777 JP): Q3 FY04/25 flash update
- Operating revenue grew 69.5% YoY to JPY5.1bn, driven by strong sales of TDM-621 across multiple regions.
- The company revised its FY04/25 forecast, expecting JPY7.0bn in revenue and a reduced operating loss of JPY769mn.
- Foreign exchange fluctuations impacted recurring loss, with JPY649mn in losses due to yen appreciation against USD and EUR.
Henry Schein: These Are The 5 Biggest Challenges That Could Hinder Its Growth in Future!
- Henry Schein, Inc. recently reported its earnings for the fourth quarter of 2024, revealing several dynamics within its business operations and financial performance.
- The company, known for its dental and medical products distribution as well as specialty and technology services, presented mixed results indicative of market conditions and internal strategic shifts.
- Positively, Henry Schein reported global sales of $3.2 billion, marking a 5.8% growth compared to the prior year.
MIRA: Pain Management Options Expand
- MIRA Pharmaceuticals(MIRA) Company Sponsored Research Report
MIRA: Pain Management Options Expand
- MIRA Pharmaceuticals(MIRA) Company Sponsored Research Report
MIRA: Pain Management Options Expand
- MIRA Pharmaceuticals(MIRA) Company Sponsored Research Report
Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
Unlock all research summaries